Proton pump inhibitor; treatment of peptic ulcer disease.<\/p>\n
DEFINITION<\/h2>\n
Esomeprazole Gastro-resistant Tablets contain Esomeprazole Magnesium Dihydrate, Esomeprazole Magnesium Trihydrate or Esomeprazole Sodium. They are covered with a gastro-resistant coating or prepared from granules or particles covered with a gastro-resistant coating.<\/p>\n
The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n
Content of esomeprazole, C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S<\/strong><\/p>\n 95.0 to 105.0% of the stated amount.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 210 to 400 nm.<\/p>\n Solution A 11 volumes of 0.25M trisodium orthophosphate, 22 volumes of 0.5M disodium hydrogen orthophosphate and 67 volumes of water. Adjust to pH 11.0 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n (1) Disperse a quantity of powdered tablets containing the equivalent of 40 mg of esomeprazole in 5 mL of methanol, dilute to 50 mL with solution A and filter (a 0.45-\u03bcm nylon filter is suitable). Further dilute 1 volume to 200 volumes with solution A.<\/p>\n (2) 0.0008% w\/v of omeprazole BPCRS in solution A.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/strong><\/p>\n (a) Use a stainless steel column (10 cm \u00d7 4.0 mm) packed with \u03b11 -acid-glycoprotein silica gel for chiral separation (5 \u03bcm) (Chiralpak AGP is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 0.6 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use a detection wavelength of 302 nm.<\/p>\n (f) Inject 20 \u03bcL of each solution.<\/p>\n MOBILE PHASE<\/strong><\/p>\n 13 volumes of acetonitrile and 87 volumes of a solution containing 0.0025M disodium hydrogen orthophosphate and 0.005 M sodium dihydrogen orthophosphate.<\/p>\n When the chromatograms are recorded under the prescribed conditions, the relative retention with reference to esomeprazole (retention time about 5 minutes) is: (R)-omeprazole (impurity F), about 0.7.<\/p>\n SYSTEM SUITABILITY<\/strong><\/p>\n The test is not valid unless, in the chromatogram obtained with solution (2), the resolution between the peaks due to (R)-omeprazole and esomeprazole is at least 3.0.<\/p>\n CONFIRMATION<\/strong><\/p>\n The UV spectrum of the principal peak in the chromatogram obtained with solution (1) is concordant with that of the peak due to esomeprazole in the chromatogram obtained with solution (2);<\/p>\n the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak due to esomeprazole in the chromatogram obtained with solution (2).<\/p>\n Comply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n Solution A 11 volumes of 0.25M trisodium orthophosphate, 22 volumes of 0.5M disodium hydrogen orthophosphate and 67 volumes of water. Adjust to pH 11.0 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n Solution B 0.1 volumes of 10M sodium hydroxide and 10 volumes of 0.05M phosphate buffer solution pH 4.5.<\/p>\n Solution C 5.2 volumes of 1M anhydrous sodium dihydrogen orthophosphate and 63.2 volumes of 0.5M anhydrous disodium hydrogen orthophosphate and dilute to 1000 volumes with water. Adjust to pH 7.6 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n TEST CONDITIONS<\/strong><\/p>\n (a) Use Apparatus 2, rotating the paddle at 100 revolutions per minute.<\/p>\n (b) Use 700 mL of 0.05M phosphate buffer solution pH 4.5, at a temperature of 37\u00b0, as the medium.<\/p>\n PROCEDURE<\/strong><\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n (1) After 60 minutes withdraw 5 mL of the medium and filter (a 0.45-\u03bcm nylon filter is suitable). Dilute 1 volume of the filtrate to 5 volumes with solution A and retain the samples for analysis. Proceed immediately to the final stage.<\/p>\n (2) 0.0002% w\/v of omeprazole BPCRS in a mixture of 1 volume of solution A and 9 volumes of water.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/strong><\/p>\n (a) Use a stainless steel column (15 cm \u00d7 2 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (Nucleosil C18 is suitable). Use a suitable guard column.<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 0.25 mL per minute.<\/p>\n (d) Use a column temperature of 30\u00b0.<\/p>\n (e) Use a detection wavelength of 302 nm.<\/p>\n (f) Inject 10 \u03bcL of each solution.<\/p>\n MOBILE PHASE<\/strong><\/p>\n 25 volumes of solution C, 35 volumes of water and 40 volumes of acetonitrile, adjusted to pH 7.6 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n When the chromatograms are recorded under the prescribed conditions, the retention time of omeprazole is about 4 minutes.<\/p>\n SYSTEM SUITABILITY<\/strong><\/p>\n The symmetry factor of the peak due to omeprazole is between 0.8 and 2.0.<\/p>\n DETERMINATION OF CONTENT<\/strong><\/p>\n Calculate the total content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in the medium using the declared content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in omeprazole BPCRS.<\/p>\n LIMITS<\/strong><\/p>\n The amount of esomeprazole released is not more than 10% of the stated amount.<\/p>\n TEST CONDITIONS<\/p>\n (a) Use Apparatus 2, rotating the paddle at 100 revolutions per minute.<\/p>\n (b) Within 1 minute of withdrawing the medium at completion of the first stage, add 200 mL of solution B, at a temperature of 37\u00b0, to the vessel.<\/p>\n PROCEDURE<\/strong><\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n (1) After 30 minutes withdraw a sample of the medium and filter (a 0.45-\u03bcm nylon filter is suitable). To a volume of the filtrate expected to contain the equivalent of 0.1 mg of esomeprazole, add 1 volume of 0.25M sodium hydroxide and dilute to 25 volumes with solution A.<\/p>\n (2) 0.002% w\/v of omeprazole BPCRS in a mixture of 1 volume of solution A and 9 volumes of water.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/strong><\/p>\n The chromatographic conditions described under the first stage may be used.<\/p>\n SYSTEM SUITABILITY<\/strong><\/p>\n The symmetry factor of the peak due to omeprazole is between 0.8 and 2.0.<\/p>\n DETERMINATION OF CONTENT<\/strong><\/p>\n Calculate the total content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in the medium using the declared content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in omeprazole BPCRS.<\/p>\n LIMITS<\/strong><\/p>\n The amount of esomeprazole released is not less than 75% (Q) of the stated amount.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Prepare the solutions immediately before use.<\/p>\n Solution A 11 volumes of 0.25M trisodium orthophosphate, 22 volumes of 0.5M disodium hydrogen orthophosphate and 67 volumes of water. Adjust to pH 11.0 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n (1) To a quantity of powdered tablets containing the equivalent of 24 mg of esomeprazole, add 40 mL of ethanol and mix with the aid of ultrasound. Add 150 mL of solution A and further mix. Dilute with sufficient solution A to produce 250 mL and filter (a 0.45-\u03bcm nylon filter is suitable).<\/p>\n (2) Dilute 1 volume of solution (1) to 20 volumes with solution A. Dilute 1 volume of this solution to 10 volumes with water.<\/p>\n (3) 0.1% w\/v of omeprazole BPCRS and 0.0005% w\/v omeprazole impurity D EPCRS, each prepared by dissolving the reference material in 1 volume of ethanol and diluting to 5 volumes with solution A. Mix 1 volume of each solution and dilute to 10 volumes with water.<\/p>\n (4) Dilute 1 volume of solution (2) to 5 volumes with water.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/strong><\/p>\n (a) Use a stainless steel column (15 cm \u00d7 4.6 mm) packed with octylsilyl silica gel for chromatography (5 \u03bcm) (Nucleosil RP8 is suitable)<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use a detection wavelength of 280 nm.<\/p>\n (f) Inject 40 \u03bcL of each solution.<\/p>\n (g) Allow the chromatography to proceed for 5 times the retention time of omeprazole.<\/p>\n MOBILE PHASE<\/strong><\/p>\n 27 volumes of acetonitrile and 73 volumes of 0.14% w\/v solution of disodium hydrogen orthophosphate previously adjusted to pH 7.6 with orthophosphoric acid.<\/p>\n When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to omeprazole (retention time about 8 minutes) are: impurity 1, about 0.25; impurity A, about 0.35; impurity E, about 0.4; impurity D, about 0.8; impurity 2, about 1.7 and impurity C, about 4.0.<\/p>\n SYSTEM SUITABILITY<\/strong><\/p>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity D and omeprazole is at least 5.0.<\/p>\n LIMITS<\/strong><\/p>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity D is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n the area of any other secondary peak is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\n the sum of the areas of all secondary peaks is not greater than 4 times the area of the principal peak in the chromatogram obtained with solution (2) (2%).<\/p>\n Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.1%).<\/p>\n Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n Solution A 11 volumes of 0.25M trisodium orthophosphate, 22 volumes of 0.5M disodium hydrogen orthophosphate and 67 volumes of water. Adjust to pH 11.0 with orthophosphoric acid or 10M sodium hydroxide.<\/p>\n (1) To a quantity of the powdered tablets containing the equivalent of 24 mg of esomeprazole, add 40 mL of ethanol and mix with the aid of ultrasound. Add 150 mL of solution A and further mix. Dilute with sufficient solution A to produce 250 mL and filter (a 0.45-\u03bcm nylon filter is suitable). Dilute 1 volume of the resulting solution to 10 volumes with water.<\/p>\n (2) 0.0096% w\/v of omeprazole BPCRS prepared by dissolving the reference material in 1 volume of ethanol and diluting to 5 volumes with solution A. Dilute 1 volume of the resulting solution to 10 volumes with water.<\/p>\n (3) 0.1% w\/v of omeprazole BPCRS and 0.0005% w\/v omeprazole impurity D EPCRS, each prepared by dissolving the reference material in 1 volume of ethanol and diluting to 5 volumes with solution A. Mix 1 volume of each solution and dilute to 10 volumes with water.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/strong><\/p>\n The chromatographic conditions described under Related substances may be used with a detection wavelength of 302 nm.<\/p>\n SYSTEM SUITABILITY<\/strong><\/p>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity D and omeprazole is greater than 5.0.<\/p>\n DETERMINATION OF CONTENT<\/strong><\/p>\n Calculate the content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in the tablets using the declared content of C17<\/sub>H19<\/sub>N3<\/sub>O3<\/sub>S in omeprazole BPCRS.<\/p>\n The quantity of active ingredient is stated in terms of the equivalent amount of esomeprazole.<\/p>\n The impurities limited by the requirements of this monograph include impurities A, C, D and E listed under Esomeprazole Magnesium Dihydrate and Esomeprazole Magnesium Trihydrate and:<\/p>\n 1. 2-hydroxy-5-methoxybenzimidazole (5-methoxy-2-benzimidazolinone),<\/p>\n 2. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1-methyl-1H-benzimidazole and 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1-methyl-1H-benzimidazole, regioisomers.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Proton pump inhibitor; treatment of peptic ulcer disease. DEFINITION Esomeprazole Gastro-resistant Tablets contain Esomeprazole Magnesium Dihydrate, Esomeprazole Magnesium Trihydrate or Esomeprazole Sodium. They are covered with a gastro-resistant coating or prepared from granules or particles covered with a gastro-resistant coating. The tablets comply with the…<\/p>\n","protected":false},"author":5,"featured_media":13093,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-13077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=13077"}],"version-history":[{"count":5,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13077\/revisions"}],"predecessor-version":[{"id":13114,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13077\/revisions\/13114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/13093"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=13077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=13077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=13077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
First stage (pH 4.5)<\/h3>\n
Final stage (pH 6.8)<\/h3>\n
Related substances<\/h3>\n
ASSAY<\/h2>\n
LABELLING<\/h2>\n
IMPURITIES<\/h2>\n
![\"Esomeprazole](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Esomeprazole-Gastro-resistant-Tablets-1.jpg\")
<\/p>\n![\"Esomeprazole](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/Esomeprazole-Gastro-resistant-Tablets-2.jpg\")
<\/p>\n